GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Price-to-Owner-Earnings

Oxford BioMedica (LSE:OXB) Price-to-Owner-Earnings : (As of Jun. 07, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Price-to-Owner-Earnings?

As of today (2024-06-07), Oxford BioMedica's share price is £3.34. Oxford BioMedica does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Oxford BioMedica's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Oxford BioMedica was 164.35. The lowest was 39.35. And the median was 116.96.


LSE:OXB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-07), Oxford BioMedica's share price is £3.34. Oxford BioMedica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-1.63. Therefore, Oxford BioMedica's PE Ratio for today is At Loss.

As of today (2024-06-07), Oxford BioMedica's share price is £3.34. Oxford BioMedica's EPS without NRI for the trailing twelve months (TTM) ended in was £-0.64. Therefore, Oxford BioMedica's PE Ratio without NRI for today is At Loss.

During the past 13 years, Oxford BioMedica's highest PE Ratio without NRI was 193.85. The lowest was 0.00. And the median was 54.91.


Oxford BioMedica Price-to-Owner-Earnings Historical Data

The historical data trend for Oxford BioMedica's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Price-to-Owner-Earnings Chart

Oxford BioMedica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 159.74 - -

Oxford BioMedica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 159.74 - - - -

Competitive Comparison of Oxford BioMedica's Price-to-Owner-Earnings

For the Biotechnology subindustry, Oxford BioMedica's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioMedica's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Price-to-Owner-Earnings falls into.



Oxford BioMedica Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Oxford BioMedica's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.34/-1.31
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioMedica  (LSE:OXB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Oxford BioMedica Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioMedica (LSE:OXB) Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines